Biological therapy in Crohn's disease

被引：2

作者：

Gordon, JN ^{[1
]}

MacDonald, TT ^{[1
]}

机构：

[1] Univ Southampton, Southampton Gen Hosp, Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England

来源：

HOSPITAL MEDICINE | 2003年 / 64卷 / 12期

关键词：

D O I：

10.12968/hosp.2003.64.12.2361

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The discovery of the central role of tumour necrosis factor-alpha in Crohn's disease and the subsequent introduction of infliximab into routine clinical practice has transformed the treatment of refractory disease. Advances in understanding of the immunopathological basis of Crohn's disease are leading to the development of new biological therapies which are likely to play an increasing role in future.

引用

收藏

页码：708 / 712

页数：5

相关论文

共 22 条

[1] Review article: maintenance treatment of Crohn's disease [J].

Biancone, L ;

Tosti, C ;

Fina, D ;

Fantini, M ;

De Nigris, F ;

Geremia, A ;

Pallone, F .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 :31-37

[2] Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial [J].

Ehrenpreis, ED ;

Kane, SV ;

Cohen, LB ;

Cohen, RD ;

Hanauer, SB .

GASTROENTEROLOGY, 1999, 117 (06) :1271-1277

[3] Natalizumab for active Crohn's disease. [J].

Ghosh, S ;

Goldin, E ;

Gordon, FH ;

Malchow, HA ;

Rask-Madsen, J ;

Rutgeerts, P ;

Vyhnalek, P ;

Zádorová, Z ;

Palmer, T ;

Donoghue, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (01) :24-32

[4] Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial [J].

Hanauer, SB ;

Feagan, BG ;

Lichtenstein, GR ;

Mayer, LF ;

Schreiber, S ;

Colombel, JF ;

Rachmilewitz, D ;

Wolf, DC ;

Olson, A ;

Bao, WH ;

Rutgeerts, P .

LANCET, 2002, 359 (9317) :1541-1549

[5] Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease [J].

Hommes, D ;

Van Den Blink, B ;

Plasse, T ;

Bartelsman, J ;

Xu, CP ;

MacPherson, B ;

Tytgat, G ;

Peppelenbosch, M ;

Van Deventer, S .

GASTROENTEROLOGY, 2002, 122 (01) :7-14

[6] Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease [J].

Hugot, JP ;

Chamaillard, M ;

Zouali, H ;

Lesage, S ;

Cézard, JP ;

Belaiche, J ;

Almer, S ;

Tysk, C ;

O'Morain, CA ;

Gassull, M ;

Binder, V ;

Finkel, Y ;

Cortot, A ;

Modigliani, R ;

Laurent-Puig, P ;

Gower-Rousseau, C ;

Macry, J ;

Colombel, JF ;

Sahbatou, M ;

Thomas, G .

NATURE, 2001, 411 (6837) :599-603

[7] Review article: the immunoregulatory cytokine interleukin-10 - a therapy for Crohn's disease? [J].

Lindsay, JO ;

Hodgson, HJF .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (11) :1709-1716

[8]

MacDonald TT, 2000, SCAND J IMMUNOL, V51, P2

[9] Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease [J].

Monteleone, G ;

Kumberova, A ;

Croft, NM ;

McKenzie, C ;

Steer, HW ;

MacDonald, TT .

JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (04) :601-609

[10] ANTIBODIES TO INTERLEUKIN-12 ABROGATE ESTABLISHED EXPERIMENTAL COLITIS IN MICE [J].

NEURATH, MF ;

FUSS, I ;

KELSALL, BL ;

STUBER, E ;

STROBER, W .

JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (05) :1281-1290